Pharmacogenetics, the next challenge for pharmacy?

被引:25
作者
Clemerson, Jessica P.
Payne, Katherine
Bissell, Paul
Anderson, Claire
机构
[1] Univ Nottingham, Ctr Pharm Hlth & Soc, Nottingham NG7 2RD, England
[2] Univ Sheffield, ScHARR, Sheffield S1 4DA, S Yorkshire, England
[3] Univ Manchester, Manchester M13 9WU, Lancs, England
来源
PHARMACY WORLD & SCIENCE | 2006年 / 28卷 / 03期
关键词
pharmacists; pharmacogenetics; pharmacogenomics; pharmacy practice;
D O I
10.1007/s11096-006-9029-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This commentary draws attention to and raises awareness of forthcoming pharmacogenetic technologies amongst the pharmacy profession. It aims to stimulate debate around the potential role that the pharmacy profession can play in the introduction of pharmacogenetic technologies into primary healthcare. This commentary discusses potential new roles for pharmacists involving pharmacogenetic technologies, giving attention to the way the profession may need to adapt to accommodate these.
引用
收藏
页码:126 / 130
页数:5
相关论文
共 31 条
[21]  
MRTEK RG, 1989, PHARM PRACTICE SOCIA, P23
[22]  
NELSON R, 2000, GENOME PHARM HUMAN G, P22
[23]  
Nuffield Committee of Inquiry into Pharmacy, 1986, PHARM REP NUFF FDN
[24]   The human genome project: Assessing confidence in knowledge and training requirements for community pharmacists [J].
Sansgiry, SS ;
Kulkarni, AS .
AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 2003, 67 (02) :10P
[25]  
SANSGIRY SS, 2004, AM J PHARM ASS, V44, P399
[26]   Recent developments - Criteria influencing the clinical uptake of pharmacogenomic strategies [J].
Shah, J .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7454) :1482-1486
[27]   Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case [J].
Tavadia, SMB ;
Mydlarski, PR ;
Reis, MD ;
Mittmann, N ;
Pinkerton, PH ;
Shear, N ;
Sauder, DN .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (04) :628-632
[28]  
The Royal Society, 2005, PERS MED HOP REAL
[29]  
TULLY MP, 2000, INT J PHARM PRACT, V8, P188
[30]   Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine [J].
Vizirianakis, IS .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 15 (03) :243-250